Completed PHASE3 INTERVENTIONAL 2-arm NCT05899816

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Sponsor: Amgen

Conditions Atopic Dermatitis Moderate-to-severe Atopic Dermatitis

Interventions Placebo Rocatinlimab

Updated 19 times since 2023 Last updated: Nov 3, 2025 Started: Jun 7, 2023 Primary completion: Aug 26, 2024 Completion: Nov 14, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis and Moderate-to-severe Atopic Dermatitis, this trial is completed. The trial is conducted by Amgen and has accumulated 19 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

19 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Aug 2025 — Sep 2025 [monthly]

Completed PHASE3
Mar 2025 — Aug 2025 [monthly]

Completed PHASE3
Jan 2025 — Mar 2025 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 14 earlier versions

Dec 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alpharetta, United States , Atlanta, United States , Auburn Hills, United States , Bakersfield, United States , Bountiful, United States , Caledonia, United States , Canoga Park, United States , Charleston, United States , Chickasha, United States and 64 more locations